DelveInsight's “BK Virus Infection Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of BK Virus Infection, historical and forecasted epidemiology as well as the BK Virus Infection market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Unlock key insights into the BKV Infection Market! Download DelveInsight’s comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ BKV Infection Market Size
Key Takeaways from the BKV Infection Market Report
- On November 1, 2024, AiCuris Anti-infective Cures initiated its first-in-human Phase I trial of AIC468, an antisense oligonucleotide aimed at treating BK virus (BKV) infections in kidney transplant (KT) recipients. This study will assess the tolerability, safety, and pharmacokinetics of AIC468 in healthy participants. Conducted in Germany, the double-blind, randomized, placebo-controlled trial will involve 72 healthy volunteers aged 18 to 64.
- BK Polyomavirus reactivation can manifest as viruria in 30–40%, viremia in 10–20%, and BK polyomavirus-associated nephropathy (BKPyVAN) in 1–10% of recipients.
- Genotype I constitutes approximately 80% of the total cases, making it the most prevalent, followed by genotype IV, which accounts for around 15% of the total cases.
- Hemorrhagic cystitis occurs in up to 70% of allogeneic bone marrow transplant patients, while the detection rate of BK virus after transplant ranges from 50% to 80%.
- The leading BKV Infection Companies such as AlloVir, Amplyx Pharmaceuticals, SL VAXiGEN, Hybridize Therapeutics, and others.
- Promising BKV Infection Therapies such as MAU868, Ciclosporin and Mycophenolate-mofetil, and others.
Stay ahead in the competitive landscape of the BKV Infection Market. Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ BKV Infection Treatment Market Size
BKV Infection Epidemiology Segmentation in the 7MM
- Total Number of Kidney Transplant Cases, Hematopoietic Stem Cell Transplant (HSCT)
- Total Incident Cases of BKV Infections
- Total Cases of BKV Infection by Viral Genotype
- Treatable Cases of BKV Infection
Download the report to understand which factors are driving BKV Infection epidemiology trends @ BKV Infection Prevalence
BK Virus Infection Emerging Drugs
- AntiBKV: Memo Therapeutics
AntiBKV is a BK virus-neutralizing antibody isolated from humans for the treatment of BK virus infection after renal transplantation. The antibody has the properties such as highly virus neutralizing, Pico-molar affinity and optimal safety profile due to human origin (negative/positive selection) and known viral target. The product has received Fast-track Designation from the US FDA in May 2023.
- MAU868: Vera Therapeutics
MAU868 is a potent, human monoclonal antibody (immunoglobulin G, IgG1/λ isotype subclass) that neutralizes all four BKV serotypes. It recognizes a conformational epitope on the viral capsid protein, VP1, which is responsible for binding to and the infection of new cells. Vera holds an exclusive worldwide license from Amplyx Pharmaceuticals, a wholly owned subsidiary of Pfizer for the development and commercialization of MAU868 in all indications. Final results from the Phase II clinical trial of MAU868 versus placebo showed that MAU868 was well tolerated and demonstrated clinically meaningful reductions in BK antiviral activity through 36 weeks in kidney transplant patients with BK viremia.
BK Virus Infection Market Outlook
Key BK Virus Infection companies such as Memo Therapeutics, Vera Therapeutics, SymBio Pharmaceuticals, and others are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of BK Virus (BKV) Infection. Adjusting the dosing regimen of immunosuppressants, such as minimizing calcineurin inhibitors and incorporating mTOR inhibitors and leflunomide is mostly used for the treatment of BKV infection. BK-specific T-cell therapy and vaccines are emerging options for the management and prevention of BKV infection. Emerging studies may shape the future of BKV infection management by prioritizing treatment efficacy while minimizing adverse effects, ultimately optimizing graft and patient survival.
Discover the future of BKV Infection Treatments with DelveInsight's latest market report. Get expert insights and forecasts—download now! @ BKV Infection Market Drivers and Barriers
Scope of the BKV Infection Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- BKV Infection Companies- AlloVir, Amplyx Pharmaceuticals, SL VAXiGEN, Hybridize Therapeutics, and others.
- BKV Infection Therapies- MAU868, Ciclosporin and Mycophenolate-mofetil, and others.
- BKV Infection Therapeutic Assessment: BKV Infection Current Marketed and BKV Infection Emerging Therapies
- BKV Infection Market Dynamics: BKV Infection market drivers and BKV Infection market barriers
- BKV Infection Unmet Needs, KOL’s views, Analyst’s views, BKV Infection Market Access and Reimbursement
Explore the dynamics of the BKV Infection Market with DelveInsight. From market size to emerging drugs—find it all in our latest report. Read now! @ BKV Infection Ongoing Clinical Trials Analysis
Table of Content
1. Key Insights
2. Executive Summary of BK virus (BKV) Infection
3. Competitive Intelligence Analysis for BK virus (BKV) Infection
4. BK virus (BKV) Infection: Market Overview at a Glance
5. BK virus (BKV) Infection: Disease Background and Overview
6. Patient Journey
7. BK virus (BKV) Infection Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. BK virus (BKV) Infection Unmet Needs
10. Key Endpoints of BK virus (BKV) Infection Treatment
11. BK virus (BKV) Infection Marketed Products
12. BK virus (BKV) Infection Emerging Therapies
13. BK virus (BKV) Infection: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of BK virus (BKV) Infection
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
